SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about press release

03 Jul 2019 Evaluate

Lupin has informed about Press Release as regards receipt of US FDA approval by the Company for Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, which is the generic version of Omidria Intraocular Solution, 1%/0.3%, of Omeros Corporation. This is considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2322.55 -6.05 (-0.26%)
21-Apr-2026 11:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.50
Dr. Reddys Lab 1220.20
Cipla 1230.10
Zydus Lifesciences 930.90
Lupin 2322.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×